#Israel #Tel Aviv #RedHill Biopharma #Talicia #RHB-204

RedHill Biopharma's Financial and Operational Results for H1 2025

On September 5, 2025, RedHill Biopharma Ltd. (Nasdaq: RDHL) released its financial results and operational highlights for the first half of 2025. The company, based in Tel Aviv, Israel, and Raleigh, North Carolina, reported substantial progress across many fronts after undergoing extensive strategic and operational improvements.

Key Operational Highlights

During this period, RedHill initiated recruitment for its Bayer-supported Phase 2 trial, which examines the combination of opaganib and darolutamide in treating advanced prostate cancer. The progression of this research underscores a significant move towards innovative cancer therapies. Moreover, the company received positive feedback from the FDA regarding its next-generation Crohn’s disease treatment program, RHB-204. This is notable as it plans to become the first clinical study targeting patients infected with Mycobacterium avium subspecies paratuberculosis (MAP-positive) and aims to address the disease’s root cause.

Additionally, RedHill reported a notable increase in revenue from Talicia, a leading treatment for Helicobacter pylori infection, highlighting growth in net revenues and units sold compared to the same time frame in 2024. Specifically, RedHill achieved 8 million additional covered lives, raising the total to over 204 million—further solidifying Talicia's position in the market. The imminent submission of a UK Marketing Authorization Application (MAA) for Talicia is expected to bolster this growth further.

Financial Achievements

The company reported a gross profit of $2.5 million for the first half of 2025, a significant increase from $1.2 million in the same period last year. This growth is attributed to rising revenues, along with cost-free contributions from royalty and licensing revenues. Overall, RedHill demonstrated a 59% increase in net revenues, reaching $4.1 million, compared to $2.6 million in the prior year. The profitability trends illustrate RedHill's successful cost-cutting measures and operational efficiency improvements, with reduced cash burn down to $5 million from $6.2 million in 2024.

Despite a net loss of $4.1 million—a minor increase from the previous year’s $3.1 million—these figures highlight the company's commitment to minimizing operational costs following its downsizing initiatives, which reduced marketing and administrative expenses.

Legal and Regulatory Developments

RedHill experienced legal victories in 2025, including a critical $8.25 million summary judgment win in New York, coupled with an award of approximately $1.82 million for legal costs. These developments further enhance the company’s financial stability, enabling it to focus on advancing its product pipeline. Notably, funding from government collaborations has particularly fueled RedHill's innovative R&D efforts across various therapeutic areas, including oncology, gastrointestinal diseases, and infectious diseases.

Looking to the Future

Looking ahead, RedHill seems well-positioned to leverage its pipeline, focusing on treating underserved indications such as advanced prostate cancer, gastrointestinal-acute radiation syndrome (GI-ARS), and Crohn’s disease. The strategic partnerships and collaborations initiated for disease identification and treatment exploration will pave the way for innovative therapies.

In conclusion, the first half of 2025 has seen RedHill Biopharma make considerable strides in both operational reform and financial stability. With a committed team and a focus on groundbreaking research, the company looks forward to further advancements in the upcoming months. It remains dedicated to delivering treatment solutions that address pressing healthcare needs and improving the quality of life for patients worldwide.

For more information, visit RedHill Biopharma's official website at www.redhillbio.com.